Alkylating agents
Surgery, Radiation & Chemotherapy for Early-Stage Hodgkin's Lymphoma
Recruiting2 awardsPhase 2
Birmingham, Alabama
This trial is studying how well surgery, radiation therapy, and/or combination chemotherapy work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease.
Popular Filters
Trials for Mantle Cell Lymphoma Patients
Stem Cell Transplantation
Stem Cell Transplant for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial is testing a new two-step approach to treating high-risk non-Hodgkin's lymphoma. First, the patient's own blood cells are transplanted. Then, a transplant from another individual is performed. The goal is to improve the chances for long-term control of lymphoma.
Alkylating agent
Veliparib + Chemotherapy for Advanced Lymphoma
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial is testing the side effects and best dosage of a combination of veliparib, cyclophosphamide, and doxorubicin hydrochloride to treat patients with solid tumors or non-Hodgkin lymphoma that has spread or can't be removed by surgery.
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
Trials for Follicular Lymphoma Patients
Stem Cell Transplantation
Stem Cell Transplant for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial is testing a new two-step approach to treating high-risk non-Hodgkin's lymphoma. First, the patient's own blood cells are transplanted. Then, a transplant from another individual is performed. The goal is to improve the chances for long-term control of lymphoma.
Alkylating agent
Veliparib + Chemotherapy for Advanced Lymphoma
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial is testing the side effects and best dosage of a combination of veliparib, cyclophosphamide, and doxorubicin hydrochloride to treat patients with solid tumors or non-Hodgkin lymphoma that has spread or can't be removed by surgery.
Bruton's Tyrosine Kinase (BTK) Inhibitor
PCI-32765 for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing a new cancer treatment drug, PCI-32765, to see if it can treat chronic lymphocytic leukemia and small lymphocytic lymphoma in elderly people and people with 17p deletion.
Trials for CD20 Positive Patients
Chemotherapy
New Cancer Treatment for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 2 & 3
San Diego, California
This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.
Kinase Inhibitor
Ibrutinib + Rituximab for Mantle Cell Lymphoma
Recruiting1 awardPhase 2
Houston, Texas
This trial is testing ibrutinib and rituximab as a treatment for mantle cell lymphoma. Ibrutinib may stop the growth of cancer cells by blocking enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them.
Anti-tumor antibiotic, Anti-metabolites
Rituximab + Chemotherapy +/- Lenalidomide for Lymphoma
Recruiting1 awardPhase 2
Anchorage, Alaska
This trial is testing rituximab and combination chemotherapy with or without lenalidomide to treat patients with newly diagnosed stage II-IV diffuse large B cell lymphoma to see if it is more effective with or without lenalidomide.
Immunomodulatory Agent
Triple Therapy for CLL/SLL
Recruiting1 awardPhase 1
Washington, District of Columbia
This trial is studying the side effects and best dose of lenalidomide when given with ibrutinib and rituximab to treat patients with CLL or SLL that has come back, is refractory, has spread, or cannot be removed by surgery.
Monoclonal Antibodies
Odronextamab for Lymphoma
Recruiting1 awardPhase 1
Orange, California
This trial is testing a new cancer drug, given either intravenously or subcutaneously. The first part of the trial is testing different doses of the drug to see how well it works, and the second part is testing how well it works in a larger group of people.
Phase 3 Trials
Chemotherapy
New Cancer Treatment for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 2 & 3
San Diego, California
This trial is testing a new cancer treatment for children with B-cell NHL. The new treatment is based on the successful LMB-96 regimen. The trial features prospective biologic and late effect studies.
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
Recruiting2 awardsPhase 3
Lebanon, New Hampshire
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Anti-metabolites
Brentuximab Vedotin + Chemotherapy for Hodgkin's Lymphoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is studying brentuximab vedotin in combination with chemotherapy to see if it is more effective than chemotherapy alone in treating children with high risk Hodgkin lymphoma.
Corticosteroid
Combination Chemotherapy +/− Bortezomib for Lymphoma
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is comparing how well two different combination chemotherapies work in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma.
Trials With No Placebo
Kinase Inhibitor
Turalio for Leukemia
Recruiting1 awardPhase 1
Bethesda, Maryland
This trial is testing a drug called PLX3397 to see if it can help treat certain types of cancer. Eligible participants will take the drug once daily for a 28-day cycle, and will have various tests and procedures throughout the study.
Stem Cell Transplantation
Stem Cell Transplant for Non-Hodgkin's Lymphoma
Recruiting1 awardPhase 2
Saint Louis, Missouri
This trial is testing a new two-step approach to treating high-risk non-Hodgkin's lymphoma. First, the patient's own blood cells are transplanted. Then, a transplant from another individual is performed. The goal is to improve the chances for long-term control of lymphoma.
Alkylating agent
Veliparib + Chemotherapy for Advanced Lymphoma
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial is testing the side effects and best dosage of a combination of veliparib, cyclophosphamide, and doxorubicin hydrochloride to treat patients with solid tumors or non-Hodgkin lymphoma that has spread or can't be removed by surgery.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.